Stoke Therapeutics Price To Book vs. Revenue

STOK Stock  USD 12.81  1.38  12.07%   
Based on Stoke Therapeutics' profitability indicators, Stoke Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Stoke Therapeutics' ability to earn profits and add value for shareholders. At this time, Stoke Therapeutics' Price To Sales Ratio is quite stable compared to the past year. Price Sales Ratio is expected to rise to 30.42 this year, although the value of Days Sales Outstanding will most likely fall to 2.53. At this time, Stoke Therapeutics' Income Quality is quite stable compared to the past year.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.580.64
Moderately Down
Slightly volatile
For Stoke Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Stoke Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Stoke Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Stoke Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Stoke Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
0.328
Quarterly Revenue Growth
0.479
Return On Assets
(0.28)
Return On Equity
(0.52)
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Stoke Therapeutics Revenue vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Stoke Therapeutics's current stock value. Our valuation model uses many indicators to compare Stoke Therapeutics value to that of its competitors to determine the firm's financial worth.
Stoke Therapeutics is rated third in price to book category among its peers. It is rated fifth in revenue category among its peers totaling about  3,187,743  of Revenue per Price To Book. At this time, Stoke Therapeutics' Total Revenue is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Stoke Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Stoke Revenue vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Stoke Therapeutics

P/B

 = 

MV Per Share

BV Per Share

 = 
2.75 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Stoke Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
8.78 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Stoke Revenue vs Competition

Stoke Therapeutics is rated fifth in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 213.18 Million. Stoke Therapeutics holds roughly 8.78 Million in revenue claiming about 4% of equities under Health Care industry.

Stoke Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Stoke Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Stoke Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Stoke Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Stoke Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-24 K-25.2 K
Net Interest Income8.8 M9.2 M
Interest Income138 K131.1 K
Operating Income-114.8 M-109 M
Net Loss-103.4 M-98.2 M
Income Before Tax-104.7 M-99.5 M
Total Other Income Expense Net10.1 M10.6 M
Net Loss-91 M-86.4 M
Net Loss-104.7 M-99.5 M
Income Tax Expense4.6 M4.8 M
Non Operating Income Net Other150.3 K295.5 K
Change To Netincome26.3 M27.6 M
Net Loss(2.38)(2.50)
Income Quality 0.77  0.86 
Net Income Per E B T 0.83  0.75 

Stoke Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Stoke Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Stoke Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Stoke Therapeutics' important profitability drivers and their relationship over time.

Use Stoke Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Stoke Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stoke Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Stoke Therapeutics Pair Trading

Stoke Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Stoke Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Stoke Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Stoke Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Stoke Therapeutics to buy it.
The correlation of Stoke Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Stoke Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Stoke Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Stoke Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Stoke Therapeutics position

In addition to having Stoke Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Artificial Intelligence Thematic Idea Now

Artificial Intelligence
Artificial Intelligence Theme
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
Check out World Market Map.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
To fully project Stoke Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Stoke Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Stoke Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Stoke Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Stoke Therapeutics investors may work on each financial statement separately, they are all related. The changes in Stoke Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Stoke Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.